- NewsCategory：
- All Company news Industry news
common105One result
-
1031
Gotham Therapeutics Establishes A±ε☆dvanced Oncology Profiling Cascade with ProQina©↕se to Progress its Portfolio of Epitranscr§§★iptomic Drug Candidates
Gotham Therapeutics Esta←±blishes Advanced Oncology Profi≥≥ling Cascade with ProQinase to Progress its∞σ Portfolio of Epitranscriptomic Drug Candidates×φWEDNESDAY, OCTOBER 30, 2019Gotham®∑ Therapeutics, a biotechnologyσ•" company developing a novel drug cl₽✔×ass targeting RNA-modifying proteins, and×∞Ω← ProQinase, an early stage drug-discovery compa★♦Ωny, recently acquired by Malve•÷rn/PA-based Reaction Biology Corp., toda∑λ¥✔y announced that they have established an ← array of advanced biochemical andγ£ε↕ cellular assays to characteriz &e epitranscriptomic-directed♥ compounds.“Establishing tailor'÷λed target engagement, ®βcell biology, phenotypic, and in-vivo ass®φays to evaluate compounds ♣↔₹×originating from our three most advan→'ced epitranscriptomic programs in paral♥ lel is a crucial next step t®∏∏o develop our broad pip₩∏™eline towards the clinic,” said ✔≤Dr. Gerhard Müller, Chief Scientific O>←fficer of Gotham Therapeutics. € “By pursuing the full range of the reader-writδ↓ er-eraser continuum, we are able to focus π宣on targets with the most compelling links to dise←§≈&ase and advance those programs σ in tandem.”“Combining our high profi≥♥ciency in providing cδ→ustomized solutions as ea' rly stage drug-discovery services, including tail×↓∏or-made biochemical and cell-&≈∞based assays, with Gotham’s expertise in epitra★®nscriptomics, we were able <to establish in a very short time a£¶← set of customized enzymatic and cellula♣γ<≈r assays for compounds ad↑₩¶↔dressing three different mRNA-modify§←ing targets,” said Dr. Sebastian D '≤empe, Chief Executive Officer of ProQi§♣≠→nase. “We look forward to supporting Gotham as t∑≥he company advances its programs into φ∑✘↑lead optimization and to continued wo≤€→rk with the Gotham team assiδ±αsting the company to advance its broad pipeline₽& in a time-effective '©manner.”In addition tσλ≥✘o establishing a tailor-ma"Ω≥♦de profiling cascade for compounds from i♣★ts three most advancδ✘€ed programs, Gotham has also maεα✔de progress in strengthening its drug≈≈∏ discovery engine and developing its candi"σλdate base. Gotham prev™β iously completed the gene-to-lead phase for×♦ its drug discovery project tarש<₽geting the METTL3/METTL14 comβ∞plex and established a robust diδ scovery process as a platform ≈£for future projects. ♣& The company has also gen♠©erated a library of high-quality compo®≈unds tailor-made for acceλ$lerated hit generatio÷≠n and hit-to-lead expa∞λnsion against large parts of the ep≥$±itranscriptomic target space. This library 㱕includes a collection₹↑ of over 2,000 analogues cove'€α<ring over 80 distinct chemotypes that will be used to further accelerate Gotham’s drug •<✔discovery efforts as it expands its pipeline.The₩ original link:https://www.pharmafocusas∏↑↓φia.com/news/gotham-therapeutics-establishes'♦>-advanced-oncology-profiling-cascade-with-₩σ≠₩proqinase-to-progress-its-portfolio-of-epi≥¶÷transcriptomic-drug-cand€∞idates2019 Asia-pacific pharma IP α∞Leader Summit: http://en.z↑¶♣∏enseegroup.com/p/510934/will be↔Ω held in Beijing ¶ ♥ on November 14-15, and will attract ∞≠ more than 500 industry experts from d" ∏omestic and foreign pharmaceu£∞tical companies, biotechnology companie姩s, governments, associations, law firms, i ©♣ntellectual property a★≈✘gents and other companies∏∏ to attend.Official registration and consultat'<ion channels:Contact：AnnPhon®γ&™e: 021-65650305Email：Mar≈α∏keting@zenseegroup.comhttp://en.z&§ enseegroup.com/p/510934 -
1030
Gilead and Glympse Bio Announce Str★←ategic Collaboration forα' ≥ Use of Biomarker Technology in NASH Clinic≤×γΩal Development
Gilead and Glympse Bio Announce Strateg ♥π≥ic Collaboration for Use $"₹of Biomarker Technology £™γαin NASH Clinical DevelopmentTUESDAY,₹¶♣< OCTOBER 29, 2019Gilead Scien♠<ces Inc. and Glympse Bio, Inc., today ann'♦ounced that the companies have entered intπ∑o a strategic collaboration in nonalcoholi≠β∑αc steatohepatitis (N↓$☆ASH) clinical development♠π★. Glympse Bio’s proprietary synthetic biomar•↕↕kers – bioengineered to identify stage and prog✔≤≠∑ression of disease as well ↑&as early detection of tr₹Ω σeatment response – will be use§®£♦d to determine clinicalΩ>' trial participants’ stage o♠↕f disease at initial screening and to "♣∑Ωdetermine responses t÷←o study treatment in Gilead’s NASH cl★™₹inical program.“We are'÷λ excited about the op$☆πportunity to partner with ×≠♥Glympse Bio to help inform our NASH development p$≤☆€rogram,” said Mani Subramanian, MD, PhD Senior♥× Vice President, Liver Diseases, Gilead λ$ Sciences. “By utilizing this innovatε♦↕ive technology, we h✘∏ope to better characterize this complex diδ↓sease and improve our understan♥→←♦ding of how our compounds impact dise÷♠ ase progression.”Glympse Bio’s proprietary tech•¥nology, Glympse Inside™, combi≥←nes synthetic biomarkers with machine ↔≈ learning approaches to iden ₽☆→tify the stage and monitor progressio✘$☆↔n of important, complex diseases such as •€→☆cancer, fibrosis, inλδ☆flammation, and infections, in real time.“We are very excited about ♦ partnering with Gilead,¥↑δ a leader in drug develoφ€¥<pment, to help drive earlier and more favor↔↔able outcomes for patien♣δts,” said Caroline J Loewβ≥>♠, President and CEO, Glympse Bio. “Gilead’s c£₩₽βommitment to developing innov∑ ∞≥ative medicines in areas of high unme •≈t medical need aligns with our m§>✘∑ission of transforming¶ < disease detection and measuπ←σring treatment response, all with the goal of hel♠♠$ping improve the lives of patient©₽←s.”information source:pharma focus Asia≈≥♦€The original link:https:http★★♥§s:https://www.pharmafocusasi≈©a.com/news/gilead-and-glympse-bio-announ≈γce-strategic-collaboration-for-use-of-biomarker-¶ α∞technology-in-nash-clinical-develo↕≈λpment2019 Asia-pacific p>÷βharma IP Leader Summit:http://en.zenseegr♠×oup.com/p/510934/&nb☆€Ω sp;will be held in Beijing&π¥φπnbsp; on November 14-15, and will att✔☆¥ract more than 500 industry λ₩ ₩experts from domestic andλ≈ foreign pharmaceutical companies, biotechn₹↓¥>ology companies, governments, associationsΩσ, law firms, intellectual prope§σ←rty agents and other companies♥ ↑ to attend.Official regi₹₽δstration and consultatio←≠≤n channels:Contact：AnnPh₩★✘<one: 021-65650305Email：Marketing@zenseegroup.comh÷✔ttp://en.zenseegroup.co'≤☆m/p/510934 -
1029
HistoIndex Announces Global Partnerships Toγ λ¶ Expand AI-Based Digital Patho₽♣logy Platform
HistoIndex Announces Glob™ε€al Partnerships To Expand AI-Based Digit® ♠al Pathology PlatformMONDAY, OCTOBER ÷≤€28, 2019HistoIndex announces the ex≠Ω≠pansion of its AI-based digital pathology platforασ←m towards large-scale NASH preclinical prog" ∞↔rams for pharmaceutical and biotech companies to achieve quantifiable anΩγφ₽d reproducible data on therapeutic resp< ≈onses in NASH animal models,×↓σγ and to aid CROs as well as research☆↓↕ agencies in validating new m∑βodels mimicking the NASH disease.↕♥£Published preclinical stuφ≤dies have demonstrated the use of Histo<"$§Index's fully quantifiable Second Harmo©≈nic Generation (SHG) technology as a hγ☆"ighly accurate stain-free method th→π↕at can monitor the efficacy of various t®♣herapeutic agents, by quantifying more thanδ §® 450 NASH-associated parameters i§¶♦n fibrosis, inflammation, balloonin→≤<g and steatosis. The information of these'× NASH-associated parameters gathered from the♠¥ entire liver tissue, provides comprehensive inπ→<σsights on the mechanism of action of the therapeu★®≤tic agent. As a drug disco₹♠₹σvery tool, HistoIndex's SHG-enabled digital patho∑☆≥logy platform will allo®λ♦←w pharmaceutical and bi™≈δotech companies to select promis$ing lead candidates for further optimization$•₽ and make informed decisions in the ma©'nagement of their NASH ™↕drug development pipeline.In addition φ₹±₹to ongoing NASH clinical trials, HistoInd≈ ex is currently involved in multiple preclini÷♥cal studies, most of≈"→' which are conducted™₹≈ by major pharmaceutical and biotech companies,↔<↔↓ medical universities, CROs and re<↓search agencies. Notably, Histo☆← €Index has recently entered intσ♣¥o a collaboration with the A*S₽→TAR's Genome Institute of Si←↑×ngapore (GIS) to validate their in vivo a♠÷☆₹nd in vitro NASH models based on A ✘"sian-centric clinical data.£≥™ Says Professor Patr↕>↔∑ick Tan, Executive Director of the G×←→enome Institute of Si♣π₩ngapore (GIS), "At GIS, we conduct our precli₩>×↔nical studies on fatty liver involving data fπ☆✘rom animal models basedα™© on patient-derived tranλ♠₽scriptomic data. This₹★÷ has a high translational potential as it h≈π☆ elps us to pinpoint new therapeutic targets a₽✘≈↕nd their validation. Thereforeφ ₹↑, using a fully quantitative, reliable π★≈and objective pathological evaluation such as Hi≠<stoIndex's AI-based digital patho★♥↓logy platform is essential to the su'♥ccess of our efforts in ther&↓apeutic target discovery."HistoIndex is als ←o a partner with globally-renowneσ®d CRO, WuXi Apptec, in adεγ×vancing their NASH preclinical programs£≥∞× with advanced R&D and±≈★ smart imaging analysis capabilities. Publish§✘ed study data will be available for discussio★↑&•ns during networking£λ opportunities throughout AASL€ D's The Liver Meeting® in N★©ovember 2019. "We are very exc→δited to extend our AI-based SHG platform to prec₽✘¥linical studies to help companies with drugδ$ discovery programs select promising lead candida δ§tes for further optimization and subseque↑nt clinical developmentδ©," says Dr Poon Thon• g Yuen, Chief Executive Officer of HistoI>←↕ ndex. "Our SHG image anal'∏↔ysis platform has already been used to analyz→÷₹e the efficacy of a se≈"ries of promising drug ca☆☆≤∏ndidates for NASH within ₹σ¶various animal models commonly-used σ£by the industry, and we bel<λieve these preclinical♥♣ partnerships will help drive th∞e adoption of our platform significantly.♥§γ↓"information source:pharma focus Asia↕εThe original link:https:https://www.pharmλ∏ afocusasia.com/news/histoindex-ann$λounces-global-partnership<"s-to-expand-ai-based-digital-pathology-platform20♥"φ♣19 Asia-pacific pharma IP Leader Su<✘εmmit: http://en.zenseegroup.com/p/5109<π♥'34/will be held in&nb≠₽♦sp;Beijing on Nove≈×™φmber 14-15, and will attract more than 500αδ industry experts from domestic and foreign pha&↔rmaceutical companies, biotechnology comβ₹panies, governments, associations, laσ∏↑≠w firms, intellectual property ageα¶$nts and other companies to attend.Of∏γ≈™ficial registration and consu£≈ltation channels:Contact：AnnPhone: 021-65650✔☆305Email：Marketing@zenseegroup.comhttp://en.ze₩↑♣nseegroup.com/p/510934 -
1028
AVROBIO Receives Orphan¥✔♣-Drug Designation from the U.S. FDA for>☆₹ AVR‑RD‑02 for the Treatme∑nt of Gaucher Disease
AVROBIO Receives Orphan-Drug Designa ✘tion from the U.S. FDA for AVR‑RD‑02 for the T'δreatment of Gaucher DiseaseFRIDAY, OCTOBE→↔>$R 25, 2019AVROBIO, Inc., today anno€φγunced that the U.S. Food and Drug Admiε×∞αnistration (FDA) has✔↕ granted orphan-drug designation for th≥™φe Company’s investigational gene ther$"≥<apy, AVR-RD-02, for the treatment of Gaucher d¶€♦isease. AVR-RD-02 consists of the₽&✘¥ patient’s own hematopoietic stem cells, gene€λ→tically modified to express glucocerebr✔'osidase (GCase), the enzy"♣me that is deficient in Gauch★÷er disease. The Company is actively recruiting i&λ n Canada for its Phase 1/2 clinical tr§ βial of AVR-RD-02, which seeks to eva÷↔εluate the safety and efficacy of✘π> the therapy in patients with Type 1 Gaucher dis§•ease.“Under the existing standardσ∏ & of care, patients with Gaucher disease are b≠₹ound to a lifelong infusion schedule of enzyme↑<₹ replacement therapies, and still exper××ience painful and progressiveγ₽ symptoms such as debilitating muscu ®₽♥loskeletal pain and fatigue,” said B←γλ™irgitte Volck, MD, PhD, President of ✘ Research and Development at AVROBIO. “Orphan-dru♥g designation recognizes the unmet need of popσ✔₽₩ulations with rare diseases like Gauch↕Ω✔er where AVROBIO striv↑§es to transform lives by addressing thΩ≈φe underlying cause o★ ©f the disease with a single∑€ dose of gene therapy.”Orphan-d§₩β>rug designation is granted by t<£★•he FDA to drugs and biologics which are inαβ ×tended for the safe a∞£nd effective treatment, diagnosisΩ✘☆ or prevention of rare diseases or con₹ditions that affect fewer than ≤≠200,000 people in the United ★☆States. Orphan-drug deδσsignation provides certaφ <≥in incentives, which may include taxπ•λ credits towards theα≥ cost of clinical trials and prescription drδ≥ug user fee waivers.information sour≤' ₹ce:pharma focus AsiaThe original¥≤♥ link:https:https://w≥$≈<ww.pharmafocusasia.com/news/avrobio-rec©→÷∑eives-orphan-drug-designatγ≠&∑ion-from-the-us-fda-for-avrrd02♥÷-for-the-treatment-of-gauc¶₽her-disease2019 Asia-pacific pharma IP Lea↑™©≈der Summit: http://en.zensee ♦group.com/p/510934/will be held i ≤¶ n Beijing on Novem ₽ber 14-15, and will attract more t₩✘♥₽han 500 industry experts from domestic and foreig∏±§n pharmaceutical compa↔ nies, biotechnology companies, governments, assoc♥&iations, law firms, intellectual pro<<₹Ωperty agents and other companies to attend.OffiσΩδcial registration and c≤δγonsultation channels:Conta✔ ↓ct：AnnPhone: 021-65650305Email：Mφ©arketing@zenseegroup.comhtt♥↕₩p://en.zenseegroup.com/p/510α934 -
1026
AZTherapies Strengthens Neuroinflam≈ mation-Targeted Pipeline Through Acquisiti∑₩on of Smith Therapeutics
FRIDAY, OCTOBER 25, 2019AZTherapies, Inc., ≈ a biopharmaceutical company d₩π★eveloping therapeutics to exte•→±nd brain health, today announced the acquis★∑ition of Smith Therapeutics, a privateεε✔£ biopharmaceutical company with a shared₹♣✘ goal of targeting neur±®÷oinflammation to treat neurode×'φgenerative disease. Smith Therapeutics’ Fπ₹✘ounder and Chief Executiv≈"e Officer Philip Ashton-Rickardt, ₹♦λPh.D., has joined the se₹↑nior leadership team at AZTherapies as Senior ><φVice President of Im≤γmunology. Financial terms© of the acquisition were not disclosed.Sγ✔¥♥mith Therapeutics’ proprietary ¶÷★$research platform focuses on the uγ÷se of modified T cells to restore a hea×♣φ∏lthy balance of inflammatory and α↓π•regulatory cells in the brain."¥♥ To date, Smith has succe∑ ★πssfully engineered im↑᧧munosuppressive T regulatory (Treg) cellsδ÷> with Chimeric Antigenα§ Receptors (CARs) targeting brain¥♣ glial cells. Previous re• ↑βsearch has demonstrated the abil€ity of Tregs to dampen miγ§croglial activity and reduce neu ✔$↑roinflammation in models of neurodegeneration, su"αggesting their potential utilΩ↑φity in the treatment of diseases includin γ®g Progressive Supranuclear Palsy (PSP), Alzhei&♦γ∏mer’s disease, Parkinson’s dise×ase, Huntington’s disease, Amyotrophic Later"•al Sclerosis (ALS), and oth>$ers.“This acquisition rep®≤$resents a meaningful step forw☆≈∞ard for us as we continue to stre☆&>≥ngthen our leadership pos✔∑ition in the developm ←₩ent of therapies targeting neuroinλ€↓÷flammation to stop or slow the progres♥≥sion of neurodegenerative diseases,” said↕↑• David R. Elmaleh, Ph.D., Founder, CEO,≤♦€★ and Chairman of AZTherapies. δ&“We are excited to be ÷←working with Philip as we®σ£ add this cutting-edge technology to our poφ©σrtfolio of innovative programs. An esteemed÷€λ★ immunologist and inventor of the ₩₩technology, Philip brings unparalleled ex→'∏↑pertise to the company and we look forward ↓₩to advancing this CAR-Treg program furthe☆≈ ¶r into IND-enabling studies and into clinical₽' development as rapid•∞♣ly as possible.”Dr. Ashton-Rickardt commented ♥©∑™on the acquisition and★≈✘> his appointment: “Our shar♦& ↕ed rationale of targeting neuroinfla ∞mmation as the root cause of neurodegeneratiδ↑♥ve disease makes this acquisition a great strateg↓ic fit for us. With AZTherapies’↑δ© expertise in drug development and clφ§↑inical trial execution, we believe that toge&¥ther, we are well posit≥₽"ioned to advance our CAR-Treg technology and ↑≠β¥fundamentally change neurodegenerative diseas¥♠¶e progression.”Prior t ÷o launching Smith Therapeutics in 2♥★₽017, Dr. Ashton-Rickardt was Chair in I₽±₽≤mmunology at Imperial College London, Visiti↑&ng Professor, Brigham and Women’sπ≈ Hospital, Harvard Medical School, and Assoc☆₽iate Professor in the Depa ✘rtment of Pathology at the University of Chicago.εδ His work has been recognized by his peers thr<∞≤ough the award of tenure from The Unive★ rsity of Chicago and σ<by his fellow citizens as a♠β∞ recipient of the Early Career Aw↓÷↔∑ard for Scientists and Engineers from Pr×♣esident Bill Clinton. He has pub§δ'lished more than 65 p✘>→←eer-reviewed papers in more than 30 ac&→∏ademic journals (includin≈♣♦g Cell, Science, Immunity, and Nature Immunology)< , has served as an edito♥σ₹r for several academic journals, and has b맶'een a member of grant review boards globally. Dr↓♣σ≈. Ashton-Rickardt received a B.Sc. in Bi™'×"ochemistry from the University of London, King’s ¥♠♦College with honors, a P¶₽"'h.D. in Molecular Biology from the University o☆ f Edinburgh, and completed post-doctoral workπΩ× at the University of Edinburgh and♣φ the Massachusetts I≈≈nstitute of Technology in Molecular Biology an↕d Molecular Immunology, respectively.information&>π♣nbsp;source:pharma focus AsiaThe origi&↔nal link:https:https://www.pharmafocusasia.com/δ€★news/aztherapies-strengthens-neur≠←←oinflammation-targeted-pipeline-th₹®rough-acquisition-of-smith-therapeutics2019 Asia-₩✔☆¶pacific pharma IP Leader Summit: http://en.zens€♠eegroup.com/p/510934/will be held in Beij"↕ing on No×Ω€vember 14-15, and will↔≥ attract more than 500 ind≤₽✘'ustry experts from domestic and foreign ®↓αpharmaceutical companies, biotechnology companiesΩ§γγ, governments, associations, law firms, intellec&♥₽tual property agents and otλ©♦¶her companies to attend.Official regis&$•tration and consultation ₩δchannels:Contact：Ann↑₽Phone: 021-65650305Email：Marketing@zenseeg£βroup.comhttp://en.zenseegroup.com/p/510934®∏
Contact Us
Zensee_Daystar online
© 2011-2016